Get the Stockscreener App
14.18
5.34%
-0.80
Myriad Genetics Inc stock is traded at $14.18, with a volume of 866.71K.
It is down -5.34% in the last 24 hours and up +12.81% over the past month.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
See More
Previous Close:
$14.98
Open:
$15.13
24h Volume:
866.71K
Relative Volume:
0.86
Market Cap:
$1.29B
Revenue:
$823.60M
Net Income/Loss:
$-116.00M
P/E Ratio:
-10.91
EPS:
-1.3
Net Cash Flow:
$-107.30M
1W Performance:
-2.61%
1M Performance:
+12.81%
6M Performance:
-49.23%
1Y Performance:
-38.11%
1-Day Range:
$14.14
$15.18
1-Week Range:
$14.13
$15.47
52-Week Range:
$12.04
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
14.18 | 1.29B | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
532.55 | 203.70B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.23 | 151.18B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
135.37 | 38.62B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
452.77 | 37.07B | 3.90B | 887.87M | 808.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
191.04 | 33.64B | 15.41B | 1.37B | 2.11B | 7.50 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Initiated | Craig Hallum | Buy |
| Dec-10-24 | Initiated | UBS | Neutral |
| Dec-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Underperform |
| May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-21-23 | Resumed | Piper Sandler | Neutral |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Underweight |
| May-23-23 | Upgrade | Goldman | Sell → Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-06-22 | Initiated | Stephens | Equal-Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Sell |
| Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
| Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-12-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Needham | Strong Buy |
| Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
| Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-29-18 | Initiated | Goldman | Sell |
| Jan-22-18 | Reiterated | Barclays | Equal Weight |
| Jan-05-18 | Initiated | BTIG Research | Buy |
| Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
| Aug-09-17 | Reiterated | Barclays | Equal Weight |
| Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
| Jan-18-17 | Initiated | Deutsche Bank | Sell |
| Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay - MSN
Peregrine Capital Management LLC Boosts Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics Included in Forbes America’s Best Employers 2025 List - GlobeNewswire
This Healthcare Giant's Employee Satisfaction Rate Crushes Industry Average by 27% - StockTitan
Myriad Genetics (MYGN) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025 - GlobeNewswire
Pancreatic Cancer Diagnostic Market to Reach $3.2 billion, Globally, by 2035 at 5.9% CAGR: Allied Market Research - GlobeNewswire Inc.
Myriad Genetics Sets Stage for Major Q4 Financial Reveal: 3 Key Investor Conferences Follow - StockTitan
Myriad Genetics (NASDAQ:MYGN) Trading 8.3% HigherHere's What Happened - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Earns Buy Rating from Analysts at Craig Hallum - MarketBeat
Myriad Genetics secures patents for cancer MRD tests - MSN
Insiders Sold US$6.5m Of Myriad Genetics Stock Possibly Sending Warning Sign - Simply Wall St
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Genomic Biomarker Market Projected To Witness Substantial Growth, 2025-2032: Myriad Genetics, Inc., Eurofins - EIN News
PARP Inhibitor Biomarkers Market Top Players- Myriad Genetics, - openPR
Expert Outlook: Myriad Genetics Through The Eyes Of 8 Analysts - Benzinga
Craig-Hallum initiates Myriad Genetics stock with a Buy rating By Investing.com - Investing.com South Africa
MYGN Stock Might Rise on Collaboration With CancerCARE - MSN
Jennison Associates LLC Raises Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics, INTERLINK Partner To Enhance Access To Hereditary Cancer Testing - Nasdaq
Myriad Genetics and CancerCARE for Life Announce Agreement - GlobeNewswire
Major Healthcare Partnership: Myriad's Advanced Cancer Risk Test Now Available to Million-Plus Patients - StockTitan
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay - GlobeNewswire
Predictive Genetic Counselling Market Size, Trends, - openPR
Myriad Genetics and Lumea Collaborate to Enhance Access to - GlobeNewswire
Myriad Genetics Get 2 Patents for Molecular Residual Disease Assay -February 05, 2025 at 05:41 pm EST - Marketscreener.com
Myriad Genetics secures patents for cancer MRD tests By Investing.com - Investing.com South Africa
Myriad Genetics Announces Two New Patents Granted For Its Molecular Residual Disease (MRD) Assay - Marketscreener.com
Myriad Genetics Partners With Lumea To Integrate Prolaris And MyRisk Tests Into BxLink Platform - Nasdaq
Myriad Genetics and Lumea Inc. Announce Integration of Advanced Molecular Diagnostic Tests into Digital Pathology Platform BxLink - Nasdaq
Lumea and Myriad Genetics Collaborate to Enhance Access to Biomarker and Hereditary Cancer Tests in BxLink - EIN News
Pancreatic Cancer Market Size USD 5.7 Billion, Opportunities, - openPR
Blue Trust Inc. Boosts Stock Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Piper Sandler Cuts Myriad Genetics (NASDAQ:MYGN) Price Target to $14.00 - MarketBeat
Fifth Third Bancorp Sells 23,296 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Sold by Nisa Investment Advisors LLC - Defense World
Piper Sandler Issues Pessimistic Forecast for Myriad Genetics (NASDAQ:MYGN) Stock Price - Defense World
Myriad Genetics (NASDAQ:MYGN) Price Target Cut to $18.00 by Analysts at The Goldman Sachs Group - MarketBeat
Myriad Genetics Unveils Award-Winning Research on Early Prenatal Screening Technology at SMFM Conference - Nasdaq
Myriad Genetics Unveils Groundbreaking Eight Weeks’ - GlobeNewswire
Revolutionary Prenatal Test Gives Parents Answers 2 Weeks Earlier Than Ever Before - StockTitan
DNA Diagnostics Market Booming Demand: Growth Trends, Share, - openPR
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.06%
3.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):